Published in Case Rep Oncol on September 28, 2012
Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol (2015) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology (1987) 3.65
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol (2008) 3.44
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med (1991) 2.68
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res (2000) 2.39
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 2.03
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2011) 1.17
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica (2009) 1.08
Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol (2005) 1.02
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity (2011) 5.98
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity (2008) 3.94
High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity (2009) 3.13
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med (2013) 2.64
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol (2007) 2.35
Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study. Ann Surg (2011) 2.23
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08
Taming cancer by inducing immunity via dendritic cells. Immunol Rev (2007) 1.92
Recent developments in cancer vaccines. J Immunol (2011) 1.76
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum (2011) 1.51
Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci U S A (2011) 1.50
Genome-wide association study of pancreatic cancer in Japanese population. PLoS One (2010) 1.50
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol (2008) 1.44
Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum (2010) 1.44
Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer (2002) 1.43
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol (2010) 1.42
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol (2007) 1.41
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol (2014) 1.39
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology (2014) 1.38
A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity (2009) 1.33
IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans. Blood (2013) 1.31
Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas (2012) 1.31
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci (2014) 1.30
Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum (2003) 1.25
Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg (2006) 1.24
Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood (2003) 1.23
An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology (2005) 1.21
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol (2008) 1.20
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci (2013) 1.20
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2011) 1.17
Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res (2005) 1.16
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res (2005) 1.14
Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci (2009) 1.12
Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother (2005) 1.11
Human dendritic cell subsets for vaccination. J Clin Immunol (2005) 1.09
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol (2012) 1.08
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother (2005) 1.06
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology (2014) 1.06
Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology (2012) 1.05
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol (2009) 1.05
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother (2011) 1.04
Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. J Biol Chem (2009) 1.04
A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 1.03
Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol Biomarkers Prev (2011) 1.02
Brm transactivates the telomerase reverse transcriptase (TERT) gene and modulates the splicing patterns of its transcripts in concert with p54(nrb). Biochem J (2008) 1.02
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol (2011) 1.01
Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL. Eur J Immunol (2007) 1.01
Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci (2009) 1.01
Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol (2008) 1.00
Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol (2009) 1.00
Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol (2009) 1.00
Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for white, African, and East Asian Americans. Ann Surg Oncol (2011) 1.00
Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol (2002) 0.99
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol (2014) 0.98
Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma. Am J Rhinol Allergy (2016) 0.97